Home  /  Resource Library  /  Glofitamab, a Novel, Bivalent CD20 Targeting T-Cell Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Glofitamab, a Novel, Bivalent CD20 Targeting T-Cell Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Preliminary results of a phase I trial investigating bispecific glofitamab for treatment of relapsed B-cell lymphomas.